<DOC>
	<DOCNO>NCT00666653</DOCNO>
	<brief_summary>The purpose study determine whether benefit give dopamine agonist patient Parkinson 's disease already treat levodopa .</brief_summary>
	<brief_title>Effects Dopamine Agonist Pharmacodynamics Levodopa Parkinson 's Disease</brief_title>
	<detailed_description>Patients idiopathic PD base London Brain Bank criterion determine OHSU movement disorder specialist enter study . They give inform consent protocol approve Oregon Health Science University Institutional Review Board General Clinical Research Center ( GCRC ) Review Committee . Patients long-term levodopa therapy , motor fluctuation dyskinesia determine screening . Subjects screen finger tapping ( FT ) practically define OFF motor state , LD overnight , practically define ON motor state . To qualify , minimum 10 % improvement ON state . The trial randomize , double-blind , placebo-controlled crossover study subject pramipexole 4 week identically appear placebo 4 week . The response two-hour LD infusion 0.5 ( threshold ) 1.0 ( suprathreshold ) mg/kg/hr examine end 4 week treatment period . The primary outcome finger-tapping speed , surrogate marker bradykinesia , seven hour time period . The area curve ( AUC ) calculate finger tap x minute ( FTM ) . Secondary outcome measure include peak motor response , measure FT , walk speed , dyskinesia , time-to-ON ( defined 10 % increase finger tap speed baseline ) , effect LD infusion subject ' perceive mood , anxiety fatigue . Subjects randomize receive either pramipexole ( PPX ) placebo initial 5 week study . The PPX placebo titrate 9 day target dose 1.0mg TID . If already take DA , taper discontinue study medication titrate upward . Their LD continue accord subject normal schedule time period , well antiparkinsonian medication take . After maintenance phase 4 week study medication ( PPX 1.0mg TID placebo TID ) subject admitted even inpatient GCRC OHSU . Their last LD dose give later 10 pm PD medication withhold 10 pm . They practice FT session night admission . At 7 AM next morning , dose study drug give IV line place . An IV levodopa infusion administer start 9 , continuously 2 hour rate either 0.5mg/kg/hr 1.0 mg/kg/hr . The infusion rate blind randomize . The infusion stop 11 . After 2:00 PM subject deem `` '' , usual antiparkinson medication reinstituted . FT , tremor , walk ( timed # step ) , dyskinesia , `` global '' PD scale measure research nurse , subject complete visual analogue scale ( VASs ) anxiety , fatigue mood every 30 minute 7:00 AM 2:00 PM .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Dopamine Agonists</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Dopamine Agents</mesh_term>
	<criteria>Age 3080 Idiopathic PD Hoehn &amp; Yahr stage 24 , diagnose 2 3 cardinal motor feature Fluctuation response levodopa Dyskinesia No historical , laboratory physical sign suggest alternate diagnosis No significant dementia , MMSE &gt; 24 On oral levodopa therapy dementia psychosis severe anxiety unstable cardiovascular disease uncontrolled hypertension history cardiac arrhythmias active peptic ulcer disease anemia ( HCT &lt; 32 % )</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>Dopamine Agonist</keyword>
	<keyword>Levodopa</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Dyskinesia</keyword>
</DOC>